Alligator Bioscience
ISIN: SE0000767188 | Ticker: ATORX | LEI: 549300E15VI0MB7LXV19
Country: Sweden
Alligator develops antibody-based pharmaceuticals for cancer treatment. The company specializes in the development of tumor-directed immunotherapies, in particular agonistic mono- and bispecific antibodies. The company is active in the early stages of drug development, from idea to clinical phase 2 studies and beyond.
Alligator Bioscience has global headquarters in Lund, Sweden, and is listed on Nasdaq Stockholm (ticker: ATORX).
2001
Served areaWorldwide
HeadquartersScheelevägen 2, 22381 Lund – Sweden
| Line item in (sek) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Assets | N/A | 151,938,000.00 | 333,200,000.00 | 169,584,000.00 |
| Noncurrent Assets | N/A | 41,593,000.00 | 33,587,000.00 | 46,770,000.00 |
| Other Property Plant And Equipment | N/A | 8,600,000.00 | 4,355,000.00 | 1,386,000.00 |
| Computer Software | N/A | 332,000.00 | 201,000.00 | 70,000.00 |
| Other Noncurrent Receivables | N/A | N/A | 0.00 | 1,815,000.00 |
| Current Assets | N/A | 110,345,000.00 | 299,613,000.00 | 122,814,000.00 |
| Current Trade Receivables | N/A | 0.00 | 7,446,000.00 | 13,930,000.00 |
| Other Current Receivables | N/A | 4,924,000.00 | 7,044,000.00 | 3,636,000.00 |
| Cash and cash equivalents | 93,890,000.00 | 103,342,000.00 | 278,148,000.00 | 97,305,000.00 |
| Equity And Liabilities | N/A | 151,938,000.00 | 333,200,000.00 | 169,584,000.00 |
| Equity | 258,498,000.00 | 115,244,000.00 | 282,273,000.00 | 89,051,000.00 |
| Issued Capital | N/A | 28,555,000.00 | 88,234,000.00 | 88,614,000.00 |
| Retained Earnings | N/A | -576,052,000.00 | -717,792,000.00 | -911,463,000.00 |
| Additional Paidin Capital | N/A | 662,741,000.00 | 911,831,000.00 | 911,901,000.00 |
| Equity Attributable To Owners Of Parent | N/A | 115,244,000.00 | 282,273,000.00 | 89,051,000.00 |
| Noncurrent Liabilities | N/A | 5,975,000.00 | 3,511,000.00 | 16,003,000.00 |
| Other Noncurrent Liabilities | N/A | 135,000.00 | 0.00 | N/A |
| Current Liabilities | N/A | 30,719,000.00 | 47,416,000.00 | 64,529,000.00 |
| Trade And Other Current Payables To Trade Suppliers | N/A | 6,538,000.00 | 9,367,000.00 | 13,343,000.00 |
| Current Accruals And Current Deferred Income Including Current Contract Liabilities | N/A | N/A | 29,586,000.00 | 39,655,000.00 |
| Other Current Liabilities | N/A | 1,879,000.00 | 2,237,000.00 | 3,032,000.00 |
| Line item in (sek) | 01.01.2020/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
|---|---|---|---|
| Revenue From Contracts With Customers | 4,352,000.00 | 12,943,000.00 | 35,696,000.00 |
| Other Income | 2,315,000.00 | 2,183,000.00 | 1,439,000.00 |
| Employee Benefits Expense | 55,710,000.00 | 57,814,000.00 | 68,836,000.00 |
| Depreciation And Amortisation Expense | 11,522,000.00 | 11,144,000.00 | 11,767,000.00 |
| Other Expense By Nature | 1,413,000.00 | 751,000.00 | 1,597,000.00 |
| Profit Loss From Operating Activities | -144,298,000.00 | -141,565,000.00 | -192,789,000.00 |
| Finance Income | 2,001,000.00 | -2,000.00 | 32,000.00 |
| Finance Costs | 1,191,000.00 | 169,000.00 | 646,000.00 |
| Profit Loss Before Tax | -143,296,000.00 | -141,736,000.00 | -193,403,000.00 |
| Income Tax Expense Continuing Operations | 0.00 | 0.00 | 0.00 |
| Profit (loss) | -143,296,000.00 | -141,736,000.00 | -193,403,000.00 |
| Profit Loss Attributable To Owners Of Parent | -143,296,000.00 | -141,736,000.00 | -193,403,000.00 |
| Line item in (sek) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Profit (loss) | N/A | -143,296,000.00 | -141,736,000.00 | -193,403,000.00 |
| Adjustments For Depreciation And Amortisation Expense | N/A | 11,522,000.00 | 11,144,000.00 | 11,767,000.00 |
| Adjustments For Sharebased Payments | N/A | 42,000.00 | 4,000.00 | 99,000.00 |
| Other Adjustments For Noncash Items | N/A | 0.00 | 65,000.00 | -19,000.00 |
| Interest Paid Classified As Operating Activities | N/A | 347,000.00 | 235,000.00 | 646,000.00 |
| Interest Received Classified As Operating Activities | N/A | 218,000.00 | 0.00 | N/A |
| Cash Flows From Used In Operating Activities | N/A | -141,352,000.00 | -127,033,000.00 | -172,607,000.00 |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | N/A | 102,000.00 | 45,000.00 | 440,000.00 |
| Cash Flows From Used In Investing Activities | N/A | 156,886,000.00 | -45,000.00 | -440,000.00 |
| Proceeds From Issuing Shares | N/A | 0.00 | 342,665,000.00 | 380,000.00 |
| Payments To Acquire Or Redeem Entitys Shares | N/A | N/A | 0.00 | 380,000.00 |
| Repayments Of Borrowings Classified As Financing Activities | N/A | 354,000.00 | 301,000.00 | 104,000.00 |
| Payments Of Lease Liabilities Classified As Financing Activities | N/A | 5,794,000.00 | 6,672,000.00 | 7,806,000.00 |
| Cash Flows From Used In Financing Activities | N/A | -6,148,000.00 | 301,795,000.00 | -7,827,000.00 |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | N/A | 145,000.00 | 60,000.00 | 32,000.00 |
| Increase (decrease) in cash and cash equivalents after effect of exchange rate changes | N/A | 9,386,000.00 | 174,717,000.00 | -180,875,000.00 |
| Cash and cash equivalents | 93,890,000.00 | 103,342,000.00 | 278,148,000.00 | 97,305,000.00 |
Please note that some sums might not add up.
| Date | Trading entity / Person | Association | Trade type | Volume |
|---|---|---|---|---|
| 27.10.22 | Sören Bregenholt Frederiksen | Other | Buy | SEK 72,748.00 |
| 25.10.22 | Marie Svensson | Other | Buy | SEK 16,632.00 |
| 19.08.22 | Sören Bregenholt Frederiksen | Other | Buy | SEK 25,726.10 |
| 18.08.22 | Sören Bregenholt Frederiksen | Other | Buy | SEK 56,911.35 |
| 31.05.22 | Peter Ostler | Other | Buy | SEK 151,500.00 |
| 04.05.22 | Sören Bregenholt Frederiksen | Other | Buy | SEK 50,895.00 |
| 02.05.22 | Sören Bregenholt Frederiksen | Other | Buy | SEK 50,811.00 |
| 30.04.22 | Sören Bregenholt Frederiksen | Other | Buy | SEK 51,171.00 |
| 26.11.21 | Anders Ekblom | Other | Buy | SEK 111,806.00 |
| 25.11.21 | Peter Ellmark | Other | Other | SEK 36,000.00 |
SE0000767188
LEI549300E15VI0MB7LXV19
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.